Description
Reliably advance your neurodegenerative disease research with a high-quality, isogenic APOE e4 homozygous human induced pluripotent stem cell (hiPSC) line, SCTi003-A-1. Derived from the well-characterized SCTi003-A healthy control hiPSC line, SCTi003-A-1 was generated through CRISPR-Cas9-mediated editing of the endogenous Apolipoprotein E (APOE) APOE e3 allele in SCTi003-A (APOE e3/e4 genotype). Validated by sequencing and free of off-target modifications, SCTi003-A-1 provides a valuable tool for studying late-onset Alzheimer's disease (AD), where APOE e4 homozygosity significantly increases risk and accelerates pathology.
SCTi003-A-1 is manufactured under rigorous quality control procedures with a culture system that includes mTeSR™ Plus, Corning® Matrigel® hESC-Qualified Matrix, and ReLeSR™, ensuring optimal performance and batch-to-batch reproducibility. SCTi003-A-1 maintains karyotypic stability and trilineage differentiation potential and is registered with hPSCreg® to support ethical sourcing and compliance with international standards.
Compatible with STEMdiff™ neural and glial differentiation protocols, this line is an ideal hiPSC model for investigating APOE4-associated neurodegenerative mechanisms or for use in genotype-specific drug screening workflows. For control-matched experiments, refer to Healthy Control Human iPSC Line, Female, SCTi003-A. For alternative genotypes, see all of our healthy control hiPSC lines.
This research-use-only product has been consented for both academic and commercial research applications under Institutional Review Board-approved protocols. Whole exome and whole genome sequence data files are available upon request. Please contact us for pricing.
Certain products are only available in select territories. Please contact your sales representative or Product & Scientific Support for further information.
